Top High Growth Tech Stocks To Watch In September 2024
In This Article:
Over the last 7 days, the market has dropped 2.7%. As for the longer term, the market has risen by 21% in the last year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that can capitalize on these trends becomes crucial for investors looking to maximize their returns.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
| Sarepta Therapeutics | 24.22% | 44.94% | ★★★★★★ |
| Super Micro Computer | 20.62% | 27.13% | ★★★★★★ |
| Ardelyx | 27.44% | 65.50% | ★★★★★★ |
| G1 Therapeutics | 27.57% | 57.75% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| Ascendis Pharma | 39.71% | 68.43% | ★★★★★★ |
| Clene | 73.06% | 62.58% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Aurinia Pharmaceuticals
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for diseases with unmet medical needs in the United States, with a market cap of approximately $998.08 million.
Operations: Aurinia Pharmaceuticals generates revenue primarily through the research, development, and commercialization of therapeutic drugs, amounting to $207.11 million. The company operates within the United States market.
Aurinia Pharmaceuticals is making significant strides in the tech-driven biotech sector, with its R&D expenses reflecting a strong commitment to innovation. The company’s revenue is forecasted to grow at 17.6% annually, outpacing the US market's 8.6%. Earnings are projected to increase by an impressive 54.61% per year, highlighting robust growth prospects. Recently, Aurinia's AUR200 entered Phase 1a trials, targeting autoimmune diseases with a unique dual inhibition mechanism of BAFF and APRIL—showcasing potential for high-impact therapeutic advancements.
CI&T
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CI&T Inc. (NYSE:CINT) offers strategy, design, and software engineering services to facilitate digital transformation for businesses globally and has a market cap of $905.98 million.
Operations: The company generates revenue primarily from its computer services segment, which contributed R$2.14 billion. Gross profit margin stands at 35%.